Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of CTx-1301 vs Focalin XR in Adult ADHD
NCT04138498Phase 2Completed
- Sponsor
- Cingulate Inc.
- Start
- Dec 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CTx-1301 in attention deficit hyperactivity disorder (ADHD), sponsored by Cingulate Inc.. Started Dec 2019; status: completed.
02
Drugs
CTx-1301
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT04138498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04138498.